The global demand for novel therapies treating rare and chronic disease indications has seen biopharmaceutical companies increasingly turn to biologics as a solution. With a predicted compound annual growth rate of 6%, the global biologics market is expected to rise from $348.03 billion to $620 billion by 20321. As these therapeutics can be complex, working with a dedicated partner can help with their development, manufacture and commercialisation, ensuring essential medicines reach patients at accelerated rates.
With a global presence and proven track record, Recipharm Advanced Bio has the expertise and flexible infrastructure to support high-quality products spanning:
- RNA and plasmid: Integrated services in one facility advancing RNA and plasmid projects through the entire development and manufacturing value chain.
- Virotherapies: Progressing live viruses and viral vectors for gene therapies to market with comprehensive development and manufacturing services.
- Microbiome: Producing live biotherapeutic product (LBP) drug substances and products with cGMP clinical and commercial manufacturing.
- Fill and finish: Providing on time in full (OTIF) delivery of biologic products with fill and finish services. Our global flexible infrastructure provides the enduring platform required for nimble operations.
Taking a consultative and proactive approach, we can progress your nucleic acid, virotherapy and microbiome projects seamlessly from clinical to commercial.
References:
1. Biologics Market Size to Surpass Around US$ 620.31 Bn by 2032 (precedenceresearch.com)
Discover how Recipharm’s Advanced Bio Services can accelerate your biologics development and manufacturing. Download the brochure to explore our full capabilities.
Access here: https://www.recipharm.com/resources/progress-your-biologic-recibiopharms-comprehensive-services
Our Services